Home Cart Sign in  
Chemical Structure| 775351-61-6 Chemical Structure| 775351-61-6

Structure of Imeglimin HCl
CAS No.: 775351-61-6

Chemical Structure| 775351-61-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Imeglimin HCl is the first in a tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins.

Synonyms: EMD 387008 hydrochloride; Imeglimin hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Imeglimin HCl

CAS No. :775351-61-6
Formula : C6H14ClN5
M.W : 191.66
SMILES Code : [H]Cl.NC1=N[C@@H](C)N=C(N(C)C)N1
Synonyms :
EMD 387008 hydrochloride; Imeglimin hydrochloride
MDL No. :MFCD28167741
InChI Key :UXHLCYMTNMEXKZ-PGMHMLKASA-N
Pubchem ID :54763513

Safety of Imeglimin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse primary hepatocytes 0.25, 1, 3, or 10 mmol/l 3 hours To investigate the effects of Imeglimin on mitochondrial respiratory function, results showed that Imeglimin inhibited basal respiration, respiration coupled to ATP production, and maximal mitochondrial respiration in a concentration-dependent manner. Sci Rep. 2023 Jan 13;13(1):746
HepG2 cells 0, 1, 3, 10, 50, 100 mM 3 hours To evaluate the effects of imeglimin on PA-stimulated lipid accumulation, apoptosis, and mitochondrial dysfunction. Results showed that imeglimin significantly reduced PA-induced lipid accumulation and improved mitochondrial function. Antioxidants (Basel). 2024 Nov 18;13(11):1415
HMEC-1 cells 10 mM or 100 μM 4 hours or 24 hours Prevention of tBH- or hyperglycemia-induced endothelial cell death Cell Death Discov. 2016 Jan 18;2:15072
Mouse microglial BV2 cells 500 µM 24 hours Imeglimin significantly suppressed the HG-induced production of IL-1β and TNF-α in BV2 cells by reducing intracellular ROS levels, ameliorating mitochondrial dysfunction, and inhibiting the activation of the TXNIP–NLRP3 axis. Cells. 2024 Feb 5;13(3):284
THP-1 macrophages 100 μM 24 hours To assess the effect of imeglimin on foam cell formation and lipid accumulation. Results showed that imeglimin inhibited foam cell formation by promoting the expression of ABCA1 and ABCG1 and downregulating CD36 expression. Cells. 2025 Mar 21;14(7):472
A375 cells 2 mM 24 hours To evaluate the effects of Imeglimin on metabolic functions and ROS levels in A375 cells. Results showed that Imeglimin significantly reduced ROS levels under high glucose conditions and inhibited glycolytic function. Int J Mol Sci. 2025 Jan 24;26(3):1014

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Standard diet mice Intraperitoneal injection 250 mg/kg Single dose, measured after 1 hour To investigate the effects of Imeglimin on AMPK activity, results showed that Imeglimin significantly increased the phosphorylation of AMPKα in the liver. Sci Rep. 2023 Jan 13;13(1):746
C57BL/6J mice Choline-deficient high-fat diet (CDA-HFD)-induced metabolic dysfunction-associated steatohepatitis (MASH) model Oral 100 and 200 mg/kg Twice daily for 8 weeks To evaluate the effects of imeglimin on MASH pathophysiology. Results showed that imeglimin reduced hepatic steatosis, improved mitochondrial function, and suppressed liver fibrosis development. Antioxidants (Basel). 2024 Nov 18;13(11):1415
ApoE KO mice STZ-induced hyperglycemic ApoE KO mice Oral gavage 200 mg/kg Twice daily for 8 weeks To investigate the protective effects of Imeglimin on the development of atherosclerosis plaque formation. Results showed that Imeglimin significantly reduced plaque formation in the aortic arch, decreased migration and proliferation of vascular smooth muscle cells and macrophage infiltration, and reduced oxidative stress and inflammation. Cardiovasc Diabetol. 2024 Mar 19;23(1):105
ApoE−/− mice Streptozotocin-induced diabetic model Oral 50 mg/kg/day Once daily for 9 weeks To evaluate the effect of imeglimin on atherosclerotic plaque formation. Results showed that imeglimin significantly reduced atherosclerotic plaque area and decreased fasting glucose and LDL cholesterol levels. Cells. 2025 Mar 21;14(7):472

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.22mL

1.04mL

0.52mL

26.09mL

5.22mL

2.61mL

52.18mL

10.44mL

5.22mL

References

[1]Fouqueray P, Pirags V, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565-8.

[2]Pirags V, Lebovitz H, et al. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012 Sep;14(9):852-8.

[3]Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021 Mar;23(3):664-673

[4]Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab. 2021 Feb 23;4(2):e00211

[5]Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Drugs R D. 2015 Sep;15(3):227-32

[6]Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70

[7]Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072

 

Historical Records

Categories